Subsequently, both PARP inhibitors were approved as targeted treatments for patients with gBRCAm, HER2-negative mBC (and locally advanced BC in Europe; talazoparib is also approved for locally advanced BC in the USA) who have previously been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting [15, 20–23]. The gene discussed is ERBB2; the disease is breast cancer.